ATI-501
The oral sibling of ATI-50002, taken to phase 2 in alopecia areata and not registered since.
This programme is no longer being actively pursued.
- Developed by
- Aclaris Therapeutics
- Current phase
- Discontinued
- Indications
- Alopecia areata
- Last public activity
- September 2020
- Record confidence
- Medium
Development stopped.
Why it matters
Aclaris ran the same JAK inhibitor by mouth and on the scalp at the same time — a clean test of whether the topical failure was about the molecule or about reaching the target. Both programmes stopped. Listed as discontinued on the evidence of no registered study since 2019 rather than a sponsor announcement, hence MEDIUM.
Development history
- Phase 2
First Phase 2 trial on record: NCT03594227 — ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Aclaris Therapeutics, Inc. · n=87 · June 2018
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- ATI-501 in alopecia areata, alopecia totalis and alopecia universalis — ClinicalTrials.gov